PARI eFlow nebulizer system

DEVICE2 trials

Sponsors

Savara Inc.

Conditions

Autoimmune Pulmonary Alveolar ProteinosisCystic Fibrosis (CF)Mycobacterium Infections, Nontuberculous

Phase 2

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

CompletedNCT02702180

Savara Inc.Autoimmune Pulmonary Alveolar Proteinosis

Start: 2016-03-21End: 2019-09-27Updated: 2023-04-12

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

TerminatedNCT03597347

Savara Inc.Cystic Fibrosis (CF), Mycobacterium Infections, Nontuberculous

Start: 2019-06-20End: 2020-10-02Updated: 2023-01-10

Related Papers

IMPALA-2: choice of DLCO as a primary endpoint in aPAP

05.01 - Airway pharmacology and treatment2022-09-04

IMPALA: efficacy measures in patients who required whole lung lavage

05.01 - Airway pharmacology and treatment2022-09-04

Safety and tolerability of inhaled molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP)

05.01 - Airway pharmacology and treatment2022-09-04

Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis

New England Journal of Medicine2020-09-07104 citations